1. Introduction {#s0005}
===============

Amantadine (AMD) is an antiviral drug having a tricyclic aliphatic ring system with a primary amino group. It is clinically used in the treatment of influenza A, Parkinsonism, hepatitis C, multiple sclerosis and drug-induced extrapyramidal reactions [@bib1], [@bib2]. The exact mechanism of action in the central nervous system is not clearly understood, but evidence suggests that AMD enhances release and reuptake balance of dopamine through antagonism of the N-methyl-D-aspartate receptor [@bib2]. This helps to reduce the symptoms of Parkinsonism [@bib3] and multiple sclerosis [@bib4]. AMD has been extensively used in the poultry industry, particularly in chicken farming due to its antiviral properties for the treatment of influenza [@bib5].

After oral administration, AMD gets rapidly absorbed from the gastrointestinal tract and is excreted unchanged up to 90% of the dose in the urine [@bib6]. A sizeable amount of AMD is bound to red blood cells and about 67% to plasma proteins. The peak plasma concentration of AMD reaches in 1--4 h after ingestion. It has a large apparent volume of distribution (about 5--10 L/kg), signifying extensive tissue binding. AMD is metabolized to a small extent, mainly by N-acetylation, and has an elimination half-life of about 15 h [@bib7].

Literature of the last two decades reveals several analytical methods for the determination of AMD in animal tissues [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], biological fluids like plasma [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23] and urine [@bib22], [@bib23] and also in processed food samples [@bib14]. These methods have utilized different analytical techniques like spectrophotometry [@bib19], capillary electrophoresis [@bib15], immunochromatography [@bib13], micellar electrokinetic chromatography [@bib21], ion mobility spectrometry [@bib22], gas chromatography with flame ionization detector [@bib23], high performance liquid chromatography (HPLC) with ultraviolet [@bib18] and fluorescence detection [@bib16], liquid chromatography-tandem mass spectrometry (LC--MS/MS) [@bib14], [@bib17], [@bib20], ultra performance liquid chromatography-tandem mass spectrometry (UPLC--MS/MS) [@bib9], [@bib10], [@bib11], [@bib12] and ultra high performance liquid chromatography coupled to high resolution LTQ orbitrap mass spectrometry [@bib8]. However, as AMD does not possess any chromophoric group, a majority of these methods require prior derivatization for sample preparation which is tedious, cumbersome and time consuming. Only three methods have analyzed AMD without derivatization in human plasma with a sensitivity of 3.9 ng/mL [@bib17] and 20 ng/mL [@bib20], [@bib22] respectively. Moreover, the chromatographic analysis time was ≥ 3.5 min in these methods. A detailed summary of chromatographic methods developed for analysis of AMD in plasma samples is given in [Table 1](#t0005){ref-type="table"}. As low concentration of AMD is expected in plasma, it is essential to develop highly sensitive and selective bioanalytical methods especially for pharmacokinetic applications. The developed method is characterized by high sensitivity, selectivity and short analysis time. The method consists of a straightforward solid phase extraction (SPE) procedure without derivatization using 200 µL of plasma samples. The chromatographic turnaround time is only 2.5 min and thus can be useful for routine sample analysis where a large number of samples need to be analyzed in a short time. The method was successfully applied for a bioequivalence study in healthy Indian subjects and the reproducibility in the measurement of subject samples was demonstrated through incurred sample reanalysis (ISR).Table 1Comparative assessment of chromatographic methods developed for analysis of amantadine in plasma and urine (1997--2017).Table 1Sr. no.Detection techniqueExtraction procedureSample volumeLinear range (ng/mL)Retention time; run timeApplicationRef.1[a](#tbl1fna){ref-type="table-fn"}HPLC-fluorescenceLLE under alkaline conditions followed by derivatization50 µL rat plasma40--200012.6 min;Pharmacokinetic studies of amantadine in 8 Wistar rats[@bib16]24.0 min2LC--MSLLE under alkaline conditions200 µL human plasma3.9--10001.9 min;Bioequivalence study with 100 mg amantadine in 20 healthy volunteers[@bib17]4.0 min3[b](#tbl1fnb){ref-type="table-fn"}HPLC--UVLLE under alkaline conditions followed by derivatization200 µL rat plasma50--500012.5 min;Pharmacokinetic studies of amantadine in 6 Sprague-Dawley male rats[@bib18]30 min4[c](#tbl1fnc){ref-type="table-fn"}LC--MS/MSPP with methanol200 µL human plasma20--20003.2 min;Pharmacokinetic studies of amantadine in 8 healthy volunteers[@bib20]7.0 min5GC-FIDDerivatization followed by DLLME1000 µL human plasma and urine14--5000 in plasma and 8.7--5000 in urine19.6 min;Pharmacokinetic studies with 100 mg amantadine in 4 healthy volunteers[@bib23]22.0 min6LC--MS/MSSPE under alkaline conditions200 µL human plasma0.50--5001.80 min;Bioequivalence study with 100 mg oral dose of amantadine in 32 healthy subjectsPM2.50 min[^1][^2][^3][^4]

2. Experimental {#s0010}
===============

2.1. Chemicals and materials {#s0015}
----------------------------

Reference standards of AMD (purity 99.59%) and AMD-d6 (purity 99.99%) used as internal standard (IS) were obtained from Vivan Life Sciences (P) Ltd. (Mumbai, India). HPLC grade methanol, and analytical reagent grade ammonium formate, formic acid and sodium hydroxide (NaOH) were obtained from Merck Specialties Pvt. Ltd. (Mumbai, India). Strata-X-C 33 µ (30 mg, 1 mL) reversed-phase extraction cartridges were obtained from Phenomenex India (Hyderabad, India). Water used in the entire analysis was prepared using Milli-Q water purification system from Millipore (Bangalore, India). Blank human plasma in K~3~EDTA was obtained from Supratech Micropath (Ahmedabad, India) and was stored at −70 °C until use.

2.2. Instruments and conditions {#s0020}
-------------------------------

A Shimadzu Nexera X2 UHPLC equipped with Shimadzu LCMS-8040 triple quadrupole mass spectrometer (MS) detector (Shimadzu Corporation, Kyoto, Japan) was used. AMD and AMD-d6 were analyzed on Phenomenex Synergi™ Hydro-RP C~18~ (150 mm× 4.6 mm, 4 µm) analytical column using an isocratic mobile phase consisting of acetonitrile and 10 mM ammonium formate, pH 3.0 adjusted with 0.1% formic acid (80:20, v/v) and delivered at a flow rate of 0.8 mL/min. The column oven temperature and autosampler temperature were maintained at 40 °C and 5 °C, respectively. The injection volume was kept at 10 µL. An electrospray ionization (ESI) source operating in the positive ionization mode was used for multiple reaction monitoring (MRM) LC--MS/MS analysis. The MS conditions optimized for quantification of AMD are summarized in [Table S1](#s0080){ref-type="sec"}. Data processing was done using Shimadzu Lab Solution software.

2.3. Preparation of stock solutions, calibration standards and quality control samples {#s0025}
--------------------------------------------------------------------------------------

A stock solution of AMD (1000 µg/mL) was prepared by dissolving requisite amount in methanol. Working solutions were prepared by diluting the stock solution with methanol. The stock and working solutions were stored at 2--8 °C. Stock solution (100 µg/mL) of AMD-d6 was prepared by dissolving 1.0 mg in 10.0 mL of methanol. Its working solution (100 ng/mL) was prepared by appropriate dilution of the stock solution in methanol. Calibration standards (CSs) and quality control (QC) samples were prepared by spiking blank plasma with working solutions. The concentration of CSs in the range of 0.50--500 ng/mL and QC samples prepared at five levels (0.05, 1.50, 30.0, 200 and 400 ng/mL) are given in [Table 2](#t0010){ref-type="table"}. All the samples prepared in plasma were kept at −70 °C until use.Table 2Method performance and linearity parameters for amantadine.Table 2Assay performanceLinearity assessmentSystem suitability[a](#tbl2fna){ref-type="table-fn"}:Linearity range (ng/mL)0.50--500 Precision (% CV)0.25/ 0.64 for retention time/area responseCalibration standards (ng/mL)0.05, 1.00, 2.00, 4.00, 10.0, 20.0, 50.0, 100, 250 and 500 Accuracy (%)97.40--102.53Quality control samples (ng/mL)0.50, 1.50, 30.0, 200 and 400System performance:Weighting factor1/*x*^2^ Signal-to-noise (S/N) ratio≥ 18Mean regression line (*y* = *mx* + *c*)*y* = (0.0245±0.0005) *x* + (0.0107±0.0009)Autosampler carryover[b](#tbl2fnb){ref-type="table-fn"}:Correlation coefficient (*r*^*2*^)≥ 0.9969 Blank plasma area response≤ 8.419 (≤ 0.15% of LLOQ area response)Precision (% CV)0.32--1.53Method ruggedness[c](#tbl2fnc){ref-type="table-fn"}:Accuracy (% change)96.3--104.9 Precision (% CV)2.71--7.40 Accuracy (%)93.85--104.15Dilution integrity[d](#tbl2fnd){ref-type="table-fn"}: Precision (% CV)0.24--1.12 Accuracy (%)97.8--104.6LLOQ and LOD (S/N ratio)0.50 ng/mL (≥ 18) and 0.18 ng/mL (≥ 10)[^5][^6][^7][^8]

2.4. Sample extraction procedure {#s0030}
--------------------------------

To an aliquot of 200 µL of spiked plasma/subject samples, 50 µL of AMD-d6 working solution was added and vortexed for 10 s. The solutions were made alkaline by adding 100 µL of 0.1 M NaOH and briefly vortexed. Samples were then loaded on Strata-X-C 33 µ extraction cartridges which were conditioned with 1.0 mL methanol, followed by 1.0 mL water. Washing of samples was done with 2 × 1.0 mL water, followed by drying of cartridges for 2.0 min by applying nitrogen (1.72 × 10^5^ Pa) at 2.4 L/min flow rate. The elution of AMD and AMD-d6 was done using 500 µL of mobile phase solution into pre-labeled vials, and 10 µL was used for injection in the chromatographic system.

2.5. Validation procedures {#s0035}
--------------------------

The method validation was performed as per the USFDA guidelines [@bib24] and was similar to our previous work [@bib25]. The detailed procedures and their acceptance criteria are summarized in [Supplementary material](#s0080){ref-type="sec"}.

2.6. Pharmacokinetic application and method reproducibility {#s0040}
-----------------------------------------------------------

The developed method was used to analyze AMD plasma concentration after oral administration of single dose of a test (100 mg of amantadine hydrochloride capsules from an Indian Pharmaceutical Company) and a reference (100 mg of amantadine hydrochloride capsules from Sandoz Pharmaceuticals Inc., Princeton, NJ, USA) formulation to 32 healthy Indian subjects under fasting. The study was conducted as per International Conference on Harmonization, E6 Good Clinical Practice Guidelines [@bib26]. The experimental details for the study are given in [Supplementary material](#s0080){ref-type="sec"}. The pharmacokinetic parameters of AMD were estimated by non-compartmental analysis using WinNonlin^®^ software version 5.3 (Certara, Princeton, NJ 08540, USA). Method reproducibility was ascertained through ISR using 134 subject samples having concentration near the C~max~ and the elimination phase in the pharmacokinetic profile of the drug and its metabolites. According to the acceptance criterion, at least two-thirds of the original and repeat results should be within 20% of each other [@bib27].

3. Results and discussion {#s0045}
=========================

3.1. LC--MS/MS method development {#s0050}
---------------------------------

Till date there are only two chromatographic methods based on mass spectrometric detection to analyze AMD in human plasma without prior derivatization [@bib17], [@bib20]. Feng et al. [@bib20] determined AMD together with some common medications like paracetamol, caffeine and chlorpheniramine maleate using protein precipitation (PP) for a pharmacokinetic study. However, the recovery was very low (\~52%) and the sensitivity of the method was 20 ng/mL for AMD. A much improved LC--MS procedure was reported by Wang and co-workers [@bib17] with a linear concentration range of 3.9--4000 ng/mL using liquid-liquid extraction (LLE). The chromatographic analysis time was 4.0 min under isocratic elution, while both the methods used a general internal standard for area ratio measurements. Thus, based on the outcome of these reports we developed a highly sensitive, selective, rapid and robust method using UHPLC--MS/MS instrumentation and SPE for sample processing employing a deuterated IS, which can give a good measure of control for extraction and ionization variability.

As both AMD and AMD-d6 have a primary amino group, mass spectrometry was performed in the positive ionization mode using ESI. Under the optimized mass spectrometric conditions, intense protonated molecular ions \[M+H\]^+^ were obtained at *m/z* 152.1 and 158.0 for AMD and AMD-d6, respectively in the full-scan mode (Q1). The product ion spectrum (Q3) provided highest signals at *m/z* 135.1 and 141.1 for AMD and AMD-d6, respectively ([Appendix A](#s0075), [Appendix A](#s0080){ref-type="sec"}). These stable product ions were obtained by the elimination of amino groups from their precursor ions. In the present work, sample cleanup was initiated on two SPE cartridges, namely, Strata-X-C and Oasis HLB, for quantitative and precise extraction recovery with minimal matrix interference. Initial trials with PP using acetonitrile and methanol yielded poor recovery of AMD with considerable matrix interference (42%--59%), while LLE with ethyl acetate, *n*-hexane, methyl *tert*-butyl ether and dichloromethane alone and in combination afforded somewhat higher recovery (\~72%) but was inconsistent at lower concentrations (0.05 and 1.50 ng/mL). With SPE under neutral conditions it was difficult to completely retain AMD (p*K*a 9.0) [@bib10] and AMD-d6 during the washing step on both the cartridges. Although the recovery obtained was precise at all QC levels, there was a loss of about 15%--18%. Thus, the solutions were made alkaline prior to loading, which led to considerable improvement in recovery (\>87%). Both the cartridges provided quantitative recovery, but Strata-X-C specifically used for weakly basic compounds (p*K*a 8--10) gave higher recoveries compared to Oasis HLB, and hence was used in the present work.

Different reversed-phase columns were assessed for a reliable and reproducible analysis of AMD. Columns tested included Kromasil C~18~ (150 mm × 4.6 mm, 3.5 µm), Hypurity C~18~ (100 mm × 4.6 mm, 5 µm), Zorbax Eclipse XDB C~18~ (150 mm × 4.6 mm, 5 µm) and Synergi Hydro-RP C~18~ (150 mm × 4.6 mm, 4 µm). Various mobile phase combinations (50:50, 60:40, 70:30 and 80:20, v/v) of acetonitrile/methanol and 5--20 mM ammonium formate at different pH (2.5--6.5) were tried during development stage. Better results were obtained with lower pH values, which correlated with the capacity factor (*K*). With increase in pH values (4.5--6.5), the *K* values were in the range of 0.4--0.6, possibly due to the formation of unionized species which had little retention. A similar trend was observed when the concentration of ammonium formate was increased from 5.0 to 20 mM. Further the impact of mobile composition showed considerable reduction in analyte response when the aqueous proportion was greater than 30%. Acetonitrile was selected ahead of methanol as it provided much better peak shape. Under the optimized mobile phase conditions of acetonitrile and 10 mM ammonium formate (pH 3.0), AMD was not adequately retained on Kromasil C~18~ and Hypurity C~18~ columns, while the response and peak shape were not acceptable on Zorbax Eclipse XDB C~18~. As a result, Synergi Hydro-RP C~18~ column which provided adequate retention, sufficient response and good peak shape was employed for further study. Additionally, use of deuterated IS helped to ensure acceptable method performance based on similar extraction recovery, chromatographic retention time and ionization response in ESI-MS/MS. The retention time for AMD and AMD-d6 was 1.80 and 1.79 min, respectively, in a total run time of 2.5 min ([Fig. 1](#f0005){ref-type="fig"}). The reinjection reproducibility (% CV) in the measurement of retention time was ≤ 1.2%.Fig. 1Representative chromatograms of (A) double blank plasma (without amantadine and amantadine-d6), (B) blank plasma spiked with amantadine-d6 (100 ng/mL), (C) amantadine (0.50 ng/mL) and amantadine-d6 (100 ng/mL) and (D) real subject sample at *C*~max~ after oral administration of 100 mg dose of amantadine.Fig. 1

The developed method was more sensitive by about 8 [@bib17] and 40 [@bib20] times compared to existing LC--MS methods in human plasma. Moreover, the analysis time was 1.5 times less than the method reported by Wang et al. [@bib17], which can be of advantage when large numbers of samples are to be analyzed, especially in a clinical setting. A comparative assessment of all chromatographic methods developed in the last two decades in plasma and urine is presented in [Table 1](#t0005){ref-type="table"}.

3.2. Assay validation results {#s0055}
-----------------------------

The results for system suitability, autosampler and column carryover, ruggedness and dilution integrity suggest acceptable assay performance as evident from the data presented in [Table 2](#t0010){ref-type="table"}. The selectivity of the method is evident from the chromatograms of double blank plasma, plasma spiked with AMD-d6, AMD at 0.50 ng/mL concentration and real subject sample at C~max~ in [Fig. 1](#f0005){ref-type="fig"}. No interference due to endogenous components was observed at the retention time of AMD and AMD-d6. Furthermore, none of the commonly used medications by human volunteers interfered at their retention times. The calibration curves showed good linearity over the established concentration range of 0.50--500 ng/mL (*r*^2^ ≥ 0.9969) for AMD. The mean values for slope, intercept, accuracy and precision data in the measurement of calibrator concentrations are shown in [Table 2](#t0010){ref-type="table"}. The intra-batch precision (% CV) ranged from 0.56% to 5.42% and the accuracy was within 98.47%--105.72% for AMD. Similarly for inter-batch experiments, the precision varied from 1.27% to 4.23% and the accuracy was within 98.86%--105.21% ([Appendix A](#s0075), [Appendix A](#s0080){ref-type="sec"}).

The mean extraction recovery and IS-normalized matrix factors (MFs) for AMD are presented in [Table 3](#t0015){ref-type="table"}. Highly precise extraction recovery in the range of 97.89%--100.28% was obtained across QC levels. The mean recovery of AMD-d6 was 98.75%. As presence of unmonitored, co-eluting compounds from the matrix can directly impact the overall performance of a validated method, it is necessary to evaluate MFs to assess the matrix effect. The IS-normalized MFs ranged from 0.981 to 1.012. Matrix effect was also checked in lipemic and haemolysed plasma samples together with normal K~3~EDTA plasma. This was determined by examining the precision (% CV) values of the slopes of the calibrations curves prepared from eight different plasma lots, which included six K~3~EDTA, one lipemic and one haemolysed plasma samples. The % CV of the slopes of calibration lines for relative matrix effect in eight different plasma lots was 1.52%, which is within the acceptance criteria of 3%--4%.Table 3Extraction recovery and matrix factor for amantadine from human plasma.Table 3Quality control level (ng/mL)Mean area response (*n* = 6)Recovery (%)Matrix factorA (post-extraction spiking)B (pre-extraction spiking)C (neat samples in mobile phase)Analyte (B/A)ISAnalyte (B/A)ISIS-normalized (Analyte/IS)400449040045029734424039100.2898.951.0151.0131.002200227620022764272334564100.0199.680.9750.9790.99530.033478032771634022397.8997.750.9841.0030.9811.5016839167041662399.2098.631.0131.0001.012[^9]

Stock solutions kept for short-term and long-term stability as well as spiked plasma solutions showed no evidence of degradation under all studied conditions. Samples for short-term stability remained stable up to 8 h, while the stock solutions of AMD and AMD-d6 were stable for minimum of 18 days at refrigerated temperature of 5 °C. As a substantial amount of AMD is bound to red blood cells, whole blood stability of AMD was also evaluated by spiking blood samples (500 µL) with AMD at 0.15 and 400 ng/mL concentrations for 2.0 h. The detailed results for stability studies are presented in [Appendix A](#s0075), [Appendix A](#s0080){ref-type="sec"}.

3.3. Application to a bioequivalence study and ISR results {#s0060}
----------------------------------------------------------

To the best of our knowledge there have been no reports on the pharmacokinetics of AMD in Indian subjects. Thus, the developed method was applied to determine plasma AMD concentration in 32 healthy Indian subjects after oral administration of 100 mg AMD capsules under fasting. The mean plasma concentration--time profiles obtained for the test and reference formulations are shown in [Fig. 2](#f0010){ref-type="fig"}. [Table 4](#t0020){ref-type="table"} summarizes mean values of pharmacokinetic parameters for both the formulations. Comparison of the results obtained with a similar study using 100 mg dose of AMD in 20 Chinese subjects [@bib17] showed no significant change in *T*~max~ and *t*~1/2~ values. However, the *C*~max~ values obtained in the present study were lower, while AUC values were somewhat higher than their results. Nevertheless, the ratios of mean log-transformed parameters, *C*~max~, AUC~0--120 h~ and AUC~0-inf~ and their 90% confidence intervals ranged from 101.23% to 102.63% and 96.14% to 108.42% for AMD, respectively, which is within the acceptance criterion of 80%--125%. These results confirm the bioequivalence of the test formulation with the reference product in terms of rate and extent of absorption. Furthermore, the assay reproducibility test performed with 134 incurred samples showed % change within±12% of the initial results, which confirms the reproducibility of the newly developed method.Fig. 2Mean plasma concentration-time profile of amantadine after oral administration of 100 mg (test and reference) capsule formulation to 32 healthy Indian subjects.Fig. 2Table 4Mean pharmacokinetic (±SD) parameters, comparison of treatment ratios and 90% CIs of natural log (Ln)-transformed parameters following oral administration of 100 mg of amantadine tablet formulation in 32 healthy Indian subjects under fasting.Table 4ParameterTestReferenceRatio (test/ reference, %)90% CI (Lower--Upper)PowerIntra subject variation (% CV)*C*~max~ (ng/mL)285.06±32.16281.58±36.64101.2396.14--107.230.99977.53AUC ~0--12\ h~ (h·ng/mL)6372.25±1047.696222.41±987.12102.4197.48--107.950.99988.09AUC ~0-inf~ (h·ng/mL)6704.26±1216.106563.53±1008.22102.6397.27--108.420.99928.33*T*~max~ (h)2.51±0.532.73±0.46--------*t*~1/2~ (h)14.21±3.6014.06±3.56--------K~el~ (1/h)0.05±0.010.05±0.01--------[^10]

4. Conclusions {#s0065}
==============

The proposed LC--MS/MS assay for the quantitation of AMD in human plasma was developed and fully validated as per current regulatory guidelines. This method can be useful for the analysis of large numbers of samples as it uses a simple extraction procedure without derivatization, requires low sample volume, is highly selective, and has a short assay time. Further, the method shows excellent accuracy and precision, reproducible recoveries and minimal matrix effects. In addition, the method was successfully applied to determine plasma AMD concentration in a bioequivalence study with healthy Indian subjects for the first time.
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[^1]: HPLC: High-performance liquid chromatography-ultraviolet; LC-MS/MS: Liquid chromatography-tandem mass spectrometry; GC-FID: Gas chromatography-flame ionization detection; LLE: Liquid--liquid extraction; PP: Protein precipitation; DLLME: Dispersive liquid-liquid microextraction; SPE: Solid phase extraction; PM: Present method.

[^2]: Together with rimantadine.

[^3]: Together with rimantadine and memantine.

[^4]: Along with paracetamol, caffeine, chlorpheniramine maleate.

[^5]: Six consecutive injections of aqueous standard mixture of amantadine (400 ng/mL) and amantadine-d6 (100 ng/mL).

[^6]: Injection sequence: extracted blank plasma → LLOQ sample → extracted blank plasma → ULOQ sample → extracted blank plasma→ ULOQ sample → extracted blank plasma.

[^7]: One QC batch analyzed on two Synergi Hydro-RP 80 Å (150 mm × 4.6 mm, 4 µm) C~18~ columns with different batch numbers, while the second batch analyzed by different analysts.

[^8]: Blank human plasma spiked with 1/5th and 1/10th dilution of the stock solution prepared at 1000 ng/mL for amantadine.

[^9]: IS: internal standard.

[^10]: SD: standard deviation CI: confidence interval; CV: coefficient of variation; *C*~max~: maximum plasma concentration; AUC~0--120\ h~: area under the plasma concentration-time curve from 0 h to 120 h; AUC~0-inf~: area under the plasma concentration-time curve from zero hour to infinity; *T*~max~: time point of maximum plasma concentration; *t*~1/2~: half life of drug elimination during the terminal phase; K~el~: elimination rate constant.
